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Abstract
The NAD+-Dependent Histone Deacetylase Sirtuin-2 is Upregulated during Myogenesis and
Promotes the Differentiation of C2C12 Myoblasts
David A. Stanton
The postnatal growth and regenerative capacity of skeletal muscle rely on the successful
activation and differentiation of muscle stem cells known as satellite cells. Although the NAD+dependent protein deacetylase sirtuin-2 (Sirt2) has been suggested to have a role as a redox
sensor during myogenesis, and in the regulation of metabolism, microtubule dynamics, and exit
from the cell cycle exit, it is not known if Sirt2 has a regulatory role in muscle stem cell
differentiation. This study aimed to elucidate the regulation of Sirt2 during the myogenic
program of muscle satellite cells. The C2C12 mouse myoblast cell line was used to examine the
regulatory mechanisms of Sirt2 during the differentiation process. Several cell lines were used
during experimentation including wild type (-) cells, cells supplemented with the Sirt2 inhibitor
BML-266, and cells which were transfected with CRISPR/Cas9 plasmids to generate both Sirt2
knockdown (SKO) and control plasmid (CC) lines. Assays were conducted at time points from
0h-96h following the induction of differentiation to assess Sirt2 regulation and downstream
interactions. Sirt2 mRNA and protein expression were elevated during the early stages of
differentiation at the 12h time point in the (-) cells. A significant decrease in the myotube fusion
index of both BML-266 and SKO cell lines was observed, indicating Sirt2 deacetylase activity is
important in regulating the normal formation of myotubes. Immunoprecipitation experimentation
was performed to evaluate Sirt2 protein interactions and possible downstream signaling targets.
Sirt2 was observed to interact with the cell cycle inhibitor retinoblastoma (pRB), as well as p21
and E2F1 a regulator of cellular proliferation. The acetylation status of E2F1 was significantly
decreased at the 12h time point coinciding with the increased Sirt2 protein expression observed
at the same point. These results indicate that Sirt2 mediates its control of myogenesis through
interaction and complex formation with proteins associated with the cell cycle, and that this
interaction mediates exit from the cell cycle and the induction of terminal differentiation leading
to the formation of myofibers. Elucidation of Sirt2 as a regulator of differentiation during
myogenesis thus presents a possible therapeutic target in conditions such as aging, as expression
of the sirtuins and their cofactor NAD+ both decrease in aged phenotypes.
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Chapter 1 – Specific Aims & Hypotheses
Introduction
The postnatal growth and regenerative capacity of skeletal muscle relies on the successful
activation of quiescent muscle stem cells known as satellite cells (SC). The satellite cell lies
between the sarcolemma and the basal lamina of a muscle fiber and was first identified by
Alexander Mauro in 1961 [1]. The process of activating these quiescent satellite cells, and the
subsequent muscle formation for the functions of growth and repair, is known as myogenesis [2].
Once activated, proliferating satellite cells may either donate their nuclei to existing muscle fibers
promoting growth, or they can differentiate and fuse to generate new muscle fibers (myotubes)
which can replace injured fibers and restore normal muscle function. The formation of new fibers
during myogenesis is termed hyperplasia, and stretch-overload experimentation performed by
Alway et al. [3] demonstrated the remarkable capacity for satellite cells to proliferate and form
new muscle fibers via this mechanism.
Investigating the molecular and genetic mechanisms that regulate myogenesis is vital, as
impaired myogenesis impacts muscular regeneration in various conditions such as aging, muscular
dystrophy, and muscle wasting (cachexia) associated with many forms of cancer [4–7]. The
occurrence of defects at any stage of myogenesis severely affects the formation of new muscle
fibers; however, the mechanisms that inhibit the function of satellite cells in various
pathophysiological conditions are characterized insufficiently [8].
Potential candidate genes that may play a role in the regulation of myogenesis include
members of the Sirtuin family [9–11]. For example, muscle-specific inactivation of the deacetylase
domain of Sirtuin1 (Sirt1; one of the seven members of the Sirtuin family) reduces myofiber size,
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impairs muscular regeneration, and suppresses muscle developmental gene expression [10]. , Sirt3
is also involved in the regulation of myoblast differentiation through mitochondrial pathways [11].
Little is known about the role of Sirt2 in myogenesis. It is known that Sirt2 shares
similarities to Sirt1, including the enzymatic regulation of essential cellular processes such as
metabolism, cellular health, and genomic stability [12–17]. In non-muscle cells, Sirt2 acts as a
universal histone deacetylase like Sirt1 [18]. Beyond its similarities to Sirt1, Sirt2 plays a role in
the proliferation of myoblasts [19], and the differentiation of several cell populations, including
oligodendroglial cells [20], and adipocytes [21]. Additionally, Sirt2 has been shown to inhibit the
E3 ubiquitin ligases to suppress tumor cell growth [22], yet downregulation of Sirt2 is protective
against ischemia-reperfusion injury in heart cells [23]. Reduced Sirt2 function directly diminishes
deacetylation of PGC-1α and expression of β-oxidation and mitochondrial genes in adipocytes
[24].
Sirt2 has several characterized roles in cell cycle regulation, including cell cycle
progression, genome stability, and mitotic exit from the cell cycle [25–27]. The retinoblastoma
family of proteins, including RB/p105 (pRB), represent attractive targets in cell cycle progression.
The pRB protein is responsible for a significant checkpoint in the G1 phase of the cell cycle
through its interaction with the E2F family of transcription factors [28] where it blocks S-phase
entry, thereby promoting terminal differentiation by inducing both cell cycle exit and tissue
specific gene expression [29]. The activity of pRB is regulated by both phosphorylation and
acetylation events, with the active form of pRB being hypo-phosphorylated and acetylated on
multiple residues. The hyper-phosphorylation of pRB by cyclin dependent kinases and the
deacetylation of pRB by histone deacetylases inhibit its activity [29,30], and Wong et al. have
previously characterized Sirt1 as a potent deacetylase for pRB [31]. Therefore, it is necessary to

3

investigate the potential interaction between Sirt2 and pRB as this could have implications for the
regulation of myogenesis.
In skeletal muscle, it has been shown that Sirt2 negatively regulates insulin resistance in
C2C12 cells [32], and induces C2C12 myoblast proliferation by activation of the ERK1/2 pathway
[19]. Additionally, there is recent evidence that Sirt2 impacts mitochondrial metabolism and
mitophagy [33,34], which is interesting as mitochondria have been implicated in the regulation of
processes which occur during myogenesis [34–36], including regulation of myoblast fusion and
differentiation.
Several studies have demonstrated that the levels of sirtuin proteins, including Sirt1-3, are
downregulated in aged conditions [37–40], and that these decreased levels are associated with
several pathological states such as increased ROS accumulation [38], Alzheimer’s disease [39],
and muscle specific conditions such as sarcopenia [40]. In addition to decreased levels of related
sirtuin proteins, overall NAD+ levels are decreased in aging which could contribute to a reduction
in the functional capacity of these sirtuins [41]. It is known that satellite cell function decreases in
aging, and the regenerative capacity of skeletal muscle suffers due to this dysfunction [42]. If Sirt2
plays a role in the regulation of satellite cell mediated myogenesis, it is feasible that the decreased
Sirt2 protein levels exhibited in aging may be involved in this dysregulation. Should this be the
case, Sirt2 would represent an important potential therapeutic target for the regulation of healthy
satellite cell function in aging.
The primary objective of this study is to establish the role of Sirt2 in the myogenic
program of muscle satellite cells. The central hypothesis is that Sirt2 expression and
deacetylase activity are necessary for the regulation of the differentiation of myoblasts in
vitro, therefore, Sirt2 is required for muscle regeneration and growth. Our rationale for
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conducting this study lies in the structural and functional similarities between Sirt1 and Sirt2
[12,13,18], with the knowledge that muscle-specific inactivation of Sirt1 impairs the myogenic
program [10]. In addition to the similarities with Sirt1, the previously characterized roles of Sirt2
in cell cycle regulation, myoblast proliferation, and cellular differentiation suggest that Sirt2 may
play a major role in the regulation of myogenesis.
Specific Aim 1: Establish the role and investigate the mechanisms by which Sirt2 mediates
myoblast differentiation.
The working hypothesis is that Sirt2 levels and activity are increased during the early
differentiation of myoblasts, and the loss of Sirt2 levels inhibit myoblast differentiation, thereby
Sirt2 positively regulates the myogenic program.
Specific Aim 2: Investigate the molecular signaling networks through which Sirt2 promotes
myoblast differentiation.
The working hypothesis is that Sirt2 promotes the differentiation of myoblasts by directly
targeting and deacetylating cell cycle regulators such as pRB or E2F1. As a result of these
interactions, proliferating myoblasts exit the cell cycle and enter into the differentiation program.

Chapter 2 – Background & Significance
Satellite Cells
Skeletal muscle is a highly plastic postmitotic tissue with a high capacity for growth and
regeneration [43]. Because adult muscle fibers are terminally differentiated, their regenerative
capacity depends on a pool of myogenic stem cells known as satellite cells (SC). SC have acquired
their name from their anatomical location, which is between the basal lamina and the sarcolemma
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of myofibers [1,43]. SC are mitotically inactive and remain in the G0 phase of the cell cycle until
activation [43,44]. While SC are usually quiescent [45], upon activation, they contribute to healthy
muscle growth (hypertrophy), or muscle repair from injury or disease [46,47].
Under normal conditions, SC express the transcription factor paired-box 7 (Pax7) and
remain quiescent [48]. SC are activated in response to various molecular triggers such as exercise,
injury, or disease, and they have a remarkable ability to self-renew, expand, proliferate as
myoblasts, or differentiate to fuse with and restore damaged muscle [49]. SC are maintained
through repeated cycles of growth and regeneration, which is essential for the continued plasticity
of skeletal muscle over time. In brief, the activation of SC is characterized by their proliferation as
myoblasts, differentiation into myotubes, and subsequent fusion to form new myofibers or
supplement existing fibers. This process is known as myogenesis and is regulated by a wide range
of proteins within the muscle cells.
Myogenesis
Studies in the field of skeletal myogenesis [50–52], led to the discovery of the myogenic
regulatory factors (MRFs) consisting of MyoD, Myf5, myogenin, and MRF4 (Myf6) [53–56].
Activation of the MRF pathway drives commitment and initiates differentiation along the
myogenic lineage. Each member of the MRF family is capable of activating the other members
and maintaining its own expression through regulatory networks [57,58]. Collectively, these
pathways drive high levels of MRF expression upon activation, which locks the cell into myogenic
commitment.
Upon receiving a stimulus for activation (exercise, damage, disease, etc.) quiescent, Pax7+
SC enter into the cell cycle [59]. For muscle to maintain its regenerative potential, there must be a
continual regeneration of SC so once these SC become activated cell fate decisions will specify
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whether the SC self-renews or differentiates. It is known that these activated SC can contribute to
regenerating fibers as well as renewing the quiescent SC pool [60,61]. This is possible because SC
are heterogeneous for Myf5 expression. Pax7+ SC can give rise to both Myf5+ and Myf5- cells.
Myf5+ cells are driven towards myogenic differentiation, while Myf5- cells represent selfrenewing stem cells [44]. MyoD plays a similar role to Myf5 as it also promotes proliferation of
SC and the progression of SC towards differentiation. SC expressing MyoD will proliferate as

Figure 1: From Punch et al.

myoblasts. These proliferating myoblasts exhibit increased expression and signaling of the cell
surface receptor Notch as well as exhibiting MyoD+. This Notch signaling also prevents early
activation of MyoD which enhances the proliferative expansion of myoblasts. At this stage of the
myogenic program, a transition from Notch signaling to canonical Wnt is required to halt
proliferation and initiate terminal differentiation in myoblasts [62].Upon the switch to Wnt
signaling the proliferating myoblasts begin to form myotubes. Myotubes are multinucleated fibers
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and can fuse to damaged fibers to assist in repair. During differentiation, myogenin expression is
upregulated. Myogenin is required for the fusion of myogenic precursor cells to either new or
previously existing fibers [63]. Loss of myogenin results in a nearly complete loss of differentiated
muscle fibers and severe loss of skeletal muscle mass [63]. Figure 1 provides an overview of this
myogenic signaling.

Sirtuin 1&3
There is a keen interest in the Sirtuin family of genes as potential mediators of myogenesis.
The Sirtuin family of proteins (1-7) are class III histone deacetylases (HDACs) which require the
cofactor NAD+ as a substrate. These proteins are involved in various biological processes
including DNA regulation, metabolism, longevity, and myogenesis [10,11,64]. Several members
of the Sirtuin family have shown associations with the myogenic program. Among the seven
mammalian Sirtuins, Sirt1 is the most characterized and has been reported to regulate various
cellular processes such as oxidative stress, cell survival, cell cycling, cell differentiation, and
metabolism by deacetylating target molecules [65]. Sirt1 activation with resveratrol treatment has
been shown to attenuate the muscular pathology associated with Duchenne muscular dystrophy in
the mdx mouse model [66]. Additionally, a study of satellite cells and Sirt1 revealed that mice
with muscle-specific inactivation of Sirt1 displayed a decreased regulation of the myogenic
program [10]. These Sirt1 deficient mice have reduced myofiber size, exhibit impaired muscle
regeneration, and reveal a depression of several muscle developmental genes including MyoD
(muscle-specific transcription factor characteristic of activated satellite cells).
Sirt1 also plays a role in the myogenic differentiation program of C2C12 myoblasts through
its specific recruitment to muscle regulatory regions on chromatin and interaction with a
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MyoD/PCAF complex. This complex then interacts with histone acetyltransferase GCN5, which
controls the activity of the myogenic factor MEF2 [67]. These interactions serve to recruit Sirt1 to
the histones of these transcription factors and result in deacetylation and subsequent repression of
these muscle-specific transcription factors, thereby inhibiting C2C12 differentiation. In contrast,
Sirt1 promotes the proliferation of C2C12 myoblasts through inhibition of the cell cycle inhibitors,
p21 Waf/Cip1 and p27 Kip1 [68].
Sirtuin 3 is located within the mitochondria and is known to deacetylate and activate a
large number of mitochondrial enzymes involved in ATP production and in both the citric acid
and urea cycles [11]. Similarly to Sirt1, the Sirt3 expression is also increased with caloric
restriction in mice [69], and exercise training in mice also increased Sirt3 protein expression within
cardiac and skeletal muscle [69]. The Sirt3 expression is also modulated during aging, as
characterized by Joseph et al., elderly individuals exhibited a 50% reduction in PGC-1α and Sirt3
protein levels in skeletal muscle compared to young subjects, regardless of activity level [70]. By
contrast, another study suggested exercise training could maintain Sirt3 levels in the skeletal
muscles of both young and aged individuals [71]. The exact mechanisms behind this
downregulation of Sirt3 in aging have yet to be full elucidated. A study of the mitochondrial Sirt3
established that Sirt3 is a positive regulator of myogenic differentiation [11], as Sirt3 deficient
C2C12 myoblasts exhibited a marked decrease in the myoblast fusion index and a significant
reduction of Myogenin, MyoD, Sirtuin 1 and Troponin T protein expression.
Sirtuin 2
Sirt2, like Sirt1 and Sirt3, are grouped together as class 1 Sirtuins. Considering that both
Sirt1 and 3 have been implicated in myogenesis, we have a considerable amount of interest in Sirt2
as a potential myogenic effector. Sirt2 has been detected in many metabolically active tissues
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including the brain, muscle, liver, testes, pancreas, kidney, and adipose tissue of mice [72–74].
Sirt2 is primarily a cytosolic protein, but it can shuttle between the cytoplasm and the nucleus
during the G2/M phase of the cell cycle to deacetylate H4K16 promoting mitotic exit [75]. This
translocation appears to happen in response to mitotic stress occurring during the G2/M transition
[76]. Additionally, one of the primary functions of Sirt2 is the deacetylation of α-tubulin both in
vitro and in vivo [77].
The microtubule network is formed by the polymerization of α- and β-tubulin heterodimers
and plays a major role in the regulation of cell shape, intracellular transport, cell motility, and cell
division [78]. These tubulin subunits are subject to numerous posttranslational modifications,
including tyrosination, phosphorylation, polyglutamylation, polyglycylation, and acetylation [79].
Sirt2 is a predominantly cytoplasmic protein, and it colocalizes with microtubules and deacetylates
lysine-40 of α-tubulin both in vitro and in vivo, and the knockdown of Sirt2 via siRNA results in
tubulin hyperacetylation [77]. Sirt2 has recently been implicated in the regulation of mitophagy
through deacetylation of various mitochondrial protein targets [33], which, in addition to cell cycle
regulation, provides possible implications in the regulation of myogenesis.
In addition to α-tubulin and histone H4 substrates, Sirt2 deacetylates forkhead transcription
factors of class O, FOXO1, and FOXO3 [80–82]. Given that FOXO transcription factors are
involved in multiple cellular processes such as DNA repair, cell cycle, apoptosis, metabolism, and
aging, Sirt2 is also connected with these diverse pathways [83].
While primarily cytoplasmic Sirt2 can translocate to the nucleus and deacetylate H4K16Ac
during the G2/M phase of the cell cycle, it plays an essential role in cell cycle control [75].
Although some reports suggest Sirt2 tubulin deacetylation might regulate microtubule stability in
the mitotic spindle, and thereby control chromosome division [25], various findings demonstrate
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that Sirt2 regulates mitosis through other mechanisms. These mechanisms include deacetylation
of CDH1 and CDC20 and consequent regulation of anaphase-promoting complex (APC) activity
[73], regulation of H4K16 acetylation levels and consequent modulation of PR-SET1 activity and
H4K20me1 levels [26], deacetylation and regulation of CDK9 activity [84], and deacetylation and
consequent protection from proteasomal degradation of mitotic checkpoint BubR1 [85]. These
seemingly strong associations between Sirt2 and the cell cycle require further elucidation in the
context of myogenesis and the cell cycle withdrawal which accompanies myoblast differentiation.
To fully understand the myogenic regulation and to apply this information in rehabilitation or
recovery of muscle loss from aging and disuse, it is necessary to investigate the possible role Sirt2
may play in this process.
An interesting potential cell cycle target for Sirt2 is the retinoblastoma (RB) protein, which
is encoded for by the RB tumor suppressor gene. The RB protein is responsible for a major
checkpoint in the G1 phase of the cell cycle in which it blocks S-phase entry and keeps the cells
in a G1 growth phase, thereby Sirt2 promotes terminal differentiation by inducing both cell cycle
exit and tissue-specific gene expression [29]. The RB gene family consists of three members,
RB/p105 (pRb), p107, and RB2/p130, collectively referred to as pocket proteins. This designation
stems from the conserved binding pocket region though which pRB, p107, and RB2/p130 bind
viral oncoproteins and cellular factors such as the E2F family of transcription factors [86], which
are recognized as key regulators of cell cycle progression [87], and proliferation-associated genes
[88]. The RB family members are active when hypophosphorylated and acetylated on multiple
residues [31]. This hypophosphorylated RB is present in resting and early G1 cells and transient
phosphorylation of pRB by G1 specific cyclin dependent kinases is the main mechanism by which
pRB activity is regulated [30]. This kinase activity results in the hyperphosphorylation and of pRB
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and the dissociation of pRB-E2F complexes, enabling E2F-dependent transcription of genes that
mediate S-phase entry [29]. In addition to the phosphorylation events acetylation and deacetylation
also play important roles in regulating the activity of pRB and the pRB/E2F complex. Acetylation
of pRb occurs at the C-terminus by p300, a member of the p300/CBP (cAMP-response-elementbinding protein-binding protein) family of HAT (histone acetyltransferase) transcriptional coactivators [89]. This acetylation obstructs the phosphorylation of pRB, leading to the maintenance
of pRB in its active hypophosphorylated form. Once activated the RB proteins inhibit the activity
of the E2F transcription factors, which mediates cell cycle exit and, in the case of muscle, the
expression of late myogenic genes including MyHC [90]. The deacetylation of pRB by HDAC
proteins allows the phosphorylation of pRB by the cyclin dependent proteins resulting in the
inhibition of pRB and the progression of the cell cycle. Sirt1 has the ability to deacetylate pRB
and thus promotes the inactive hyperphosphorylated form of pRB [31]. The interaction between
the RB family proteins and the E2F family transcription factors plays a central role in governing
cell cycle progression and DNA replication by controlling the expression of cell cycle E2Fdependent genes, [91], and Sirt1 has been implicated in this regulation as an RB specific
deacetylase [31], increasing the interest in related HDAC involvement in this process.
The RB mediated repression of E2F transcription factors may be linked to the recruitment
of chromatin remodeling enzymes, including HDACs [92,93]. The pRB is able to form a complex
with the HDAC [94], which can then interact with the E2F promoter and inhibit gene expression
by blocking the access of transcription factors to the promoter [95]. Experiments in vitro have
supported this possible interaction and shown that HDAC is required for the inhibition of E2F by
RB [94], while other studies have shown only a partial requirement for HDAC activity in the RBmediated inhibition of E2F [96]. To facilitate the binding and interaction, both pRB and HDAC1
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possess a conserved LXCXE motif which allows them to bind and form the complex that
ultimately silences E2F1 transcription [94,97]
E2F1 has been shown to interact with the histone
acetyl transferases p300/CBP and p/CAF [98], so
it is possible that RB-mediated recruitment of
HDAC to E2F acts to offset this histone
acetyltransferase (HAT) activity. It has also been
shown recently that E2F1 can be acetylated, which
increases the binding of the E2F/DP complex to
DNA [99]. Therefore, recruitment of HDAC to
E2F via RB may inhibit E2F activity by
deacetylation and inhibit its binding to DNA. This
mechanism suggests there may be a potential link
between Sirt2 and the RB protein in the process of
cell cycle regulation, which is further supported as
there is growing evidence that RB has regulatory

Fig 2. Proposed interaction between Sirt2 and the RB protein in
mediated E2F transcription factor inhibition. RB recruits Sirt2 to the E2F
promoter gene where deacetylation occurs and nucleosome formation
inhibits E2F gene transcription, thereby inhibiting proliferation,
stimulating cell cycle arrest, and terminal differentiation. RB
(Retinoblastoma Protein), E2F (E2F family transcription factors), HAT
(Histone Acetyltransferases). Line with bar indicates inhibition, arrow
indicates stimulation. Several other potential regulators are included in
the model such as Sirt1/P21 etc. Figure adapted from Harbour et al. (82)

effects on the cell cycle beyond G1[92], which
could bring RB into contact with Sirt2 when it enters the nucleus during G2. One proposed
pathway for Sirt2 and RB action is depicted in figure 2, in which Sirt2 forms a complex with RB
family proteins such as pRB and is recruited to E2F family transcription factors to aid in their
inhibition. This process is likely to occur early in the differentiation program when Sirt2 is
upregulated (12, 24 hours), coinciding with increased MyoD expression. The combined action of
Sirt2 and RB will contribute to cell cycle arrest and terminal differentiation.

13

Overexpression of all three pocket proteins in cells can induce growth arrest in the G1
phase of the cell cycle linked to the upregulation of the cell cycle inhibitor p21 and the repression
of E2F regulated proliferative genes [100]. This revelation helped to define the role of the RB gene
family in regulating transition between cell proliferation and terminal differentiation [86].
Following this acute growth arrest, a more permanent cell cycle withdrawal is considered
necessary for the later stages of differentiation. This then renders myotubes conducive to the
expression of late markers including MyHC [90]. Thus, pRB fills a more accurate role throughout
the later phases of myogenesis.
The pRb protein also has a central role in various differentiation processes including the
nervous system, liver, and muscle tissue. For example, pRB is necessary for the completion of the
muscle differentiation program and myogenic helix-loop-helix dependent transcription [101]. This
regulation involves a transcriptional link between pRB and MyoD over the course of myogenesis.
It has been demonstrated that expression of pRB can upregulate MyoD transcriptional activity and
induce the expression of late muscle differentiation markers such as myosin heavy chains (MHC)
and muscle-specific creatine kinase [102]. In pRB -/- mouse embryonic fibroblasts (MEFs) the 2
remaining RB family members, p107 and p130, can partially augment MyoD transcriptional
activity and upregulate expression of MyHC and MCK, but functional pRB is required for their
full induction [103].
Recently, is was shown that Sirt2 interacts directly with mitochondrial proteins and helps
to shape mitochondrial metabolism [33]. Direct electron microscope images support that Sirt2
associates with the inner mitochondrial membrane and the loss of Sirt2 increases oxidative stress,
and dysregulates mitophagy through the loss of direct deacetylation of ATG5 by Sirt2.
Mitochondrial function and activity are linked to cell differentiation, as has been shown in a wide
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variety of cell types including myoblasts [36,104,105]. When myoblasts differentiate into
myotubes, mitochondrial enzyme activity is drastically increased [106,107], suggesting a
metabolic shift from glycolysis to oxidative phosphorylation during this time.

Chapter 3 – Research Design, Methods, and Procedures
Research Design

Figure 7: Proposed Study Design

The general study design is shown in figure 7. The model used C2C12 mouse myoblasts
to examine the regulation of Sirt2 during myogenesis. The cells were subjected to several
conditions and samples were taken from control C2C12 cells, cells which were supplemented with
the Sirt2 deacetylase inhibitor BML-266, and a group which was transfected with a Sirt2 KO
CRISPR/CAS9 plasmid and control plasmid. These myoblasts were cultured in growth media and
used for the various assays (immunoblot, immunocytochemistry, immunoprecipitation, etc.) that
were necessary for the study. Certain assays required the myoblasts to be transferred to a
differentiation medium to induce serum starvation promoting the differentiation of the myoblasts
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into myotubes. Cell samples were taken at various time points ranging from 0 hours to 96 hours,
and these time points encompass both myoblasts (early time points) and myotubes (later time
points). Samples from these various time points were used to generate a model of Sirt2 regulation
during myogenesis in support of specific aim 1.
For specific aim 2 various protein targets of interest were examined using
immunoprecipitation assays, immunoblotting, and probing for acetylation status. These assays
were used to determine the specific proteins that interact with Sirt2 at the various time points
during myogenesis. Proteins which interact with Sirt2 in immunoprecipitation assays were
subsequently evaluated with acetylated lysine antibodies to assess the acetylation status of these
proteins. The various protein targets included myogenic proteins such as Pax7, MyoD, and
myogenin. In addition to these myogenic proteins, we focused cell cycle markers such as the
retinoblastoma protein Rb/p105 (pRb). These data were used to form the proposed regulatory
model in which Sirt2 promotes the differentiation of C2C12 myoblasts through interactions with
cell cycle associated proteins and the deacetylation mechanism inherent to Sirt2.
Methods
Cell Culture
C2C12 mouse skeletal muscle myoblasts were cultured in Dulbecco’s Modified Eagle
Medium (DMEM). The proliferation media or growth media (GM) consisted of 500ml of DMEM,
50ml of fetal bovine serum (10%), and 6ml of antibiotic/antimycotic (GIBCO, Invitrogen, 15240)
(1%). The differentiation media (DM) consisted of 500ml of DMEM, 10ml of horse serum (2%),
and 5ml of A/A (1%). Cells were subcultured when confluency reached 70-80%. The plates were
washed with warm 1x PBS and the cells were dislodged by 1x trypsin treatment. The cells were
cultured in 10cm plates and terminal differentiation was induced when the cells approached 70-
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80% confluence. All cells were cultured in an incubator at 37ºC, 5% CO2, and 95% humidity. All
cell culture was conducted within a sterile culture hood which was subjected to 30 minutes of
ultraviolet light both before and after working with samples within the hood. The working surface
of the hood was also cleaned with 70% ethanol both before and after working with samples.
Differentiation
The myoblasts were cultured and placed in differentiation medium upon reaching
approximately 70-80% confluency. Differentiation was induced via serum starvation in a
differentiation medium (DMEM, 2% horse serum, 1% AA) and subsequently myoblasts and
myotubes were collected at different time points throughout myogenesis. Cells were collected at
0, 12, 24, 48, 72, and 96 hours. Various assays were conducted with the myoblasts/myotubes at
each time point including protein and immunocytochemical analysis. The cells were collected and
stored at -80ºC until needed for assays. In brief, collected cells were first washed with warm 1x
PBS to remove the media. The plates were then placed on ice and cell scrapers were used to collect
the samples which were then placed into 15 mL tubes. The collected cells and PBS were
centrifuged at 4° C, 700 G, for 5 minutes. The cell pellets were then transferred to 1.5 mL tubes,
and the supernatant (PBS) was removed and the pellets were frozen at -80° C for use in subsequent
assays.
Differentiation Assay/ Immunocytochemistry
Differentiation was induced in C2C12 myoblasts by serum withdrawal (DMEM, 2% horse
serum, 1% AA) and this differentiation was then evaluated by immunofluorescence. The cells used
were fixed on gelatin coverslips with 1:1 acetone methanol for 10 minutes at 4° C. These coverslips
were then used for subsequent immunocytochemistry. After blocking the coverslips in 1% normal
goat serum at RT for 1 hour the cells were first stained with an antibody for non-specific myosin
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heavy chain (mf20, Developmental Studies Hybridoma Bank, University of Iowa). Primary
antibodies were diluted in sterile PBS at a concentration of 1-100 and incubated with the cells at
4° overnight. Following primary antibody incubation a fluorescent secondary antibody (Alexa
Fluor 488 goat anti-mouse IgG2b) at a concentration of 1-500, the differentiation index was
calculated by counting the number of nuclei, stained with 4',6-Diamidino-2-Phenylindole,
Dihydrochloride (DAPI, Molecular probes by Life Technologies,), in a series of 5 pictures taken
from each sample. Myotubes with more than 2 nuclei per fiber were counted as differentiated
nuclei incorporated into myotubes. The differentiation index was calculated as the number of
nuclei in differentiated cells/total number of nuclei. This differentiation index or myotube fusion
index was performed with control C2C12 myoblast cells, cells which were incubated with varying
concentrations of BML-266 (1uM, 2uM, 2.5uM, 3uM) and cells which were transfected with
CRISPR/CAS9 knockdown and control plasmids.
Western Blot Analysis
Protein lysates from the samples that were collected from culture timepoints were
extracted using a RIPA (50mM Tris-cl pH 7.4, 150mM NaCl, 1% NP40, 0.25% Na-deoxycholate)
lysis buffer supplemented with 10uL sodium metavanadate, 1uL Dithiothreitol, 10 uL of protease
inhibitor cocktail (Sigma #8340), and 10 uL of phenylmethane sulfonyl fluoride for every 1 mL
of RIPA buffer. The Coomassie Blue (Bradford) protein quantification assay was conducted to
acquire the protein concentrations for samples before gel electrophoresis. Loading samples
generated for Western Blot contained 25 µg/µL of protein for each sample run. 30µL of working
solution (Protein lysate of 25ug, 1/3 volume 4x sample dye, 1.5 uL DTT, and ddH2O to volume
of 30uL) was subjected to gel electrophoresis in 4-12% bis-tris (NuPage) gel at 150 volts in MES
running buffer (950mL ddH2O, 50mL MES running stock solution, NOVEX by Life
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Technologies). The gel was then transferred to a nitrocellulose membrane at 4°C for 1 hour at 30V
in transfer buffer (850 mL ddH2O, 100mL methanol, 50mL stock transfer solution, NOVEX by
Life Technologies). The membranes were then cut at various molecular weights to isolate specific
proteins and blocked in 2% nonfat milk blocking solution for 1 hour prior to incubating overnight
with gentle rocking at 4°C in appropriate antibodies, Cell Signaling: (p21 Waf1/Cip1), (Ac-alphaTubulin), (Ac-Lysine), (Sirt3), (Lamin B1), Millipore: (Sirt1), (Sirt2), Thermo Scientific: (RB),
(E2F1), BD Pharmingen: (MyoD), Santa Cruz Biotechnology, (Myogenin), (PGC1α), Abcam:
(cyclophilin). Following overnight incubation, membranes were washed 3x in TBST for 5 minutes
each. After washing, secondary antibodies in 2% nonfat milk blocking solution were applied to
the membrane and allowed incubation at room temperature for 1 hour. Membranes were then
washed 4x for 15 minutes before exposing the membranes using SuperSignal West Dura extended
duration substrate (Thermo Scientific) for subsequent chemiluminescent detection of antibodies
using a Syngene GBOX Chemiluminescence and Fluorescence Imaging System.
Nuclear/Cytosolic Fractionation
Cells collected at various time points as described previously were used for cytosolic and
nuclear fractionation. Cell pellets were homogenized on ice in 200 uL of ice cold lysis buffer
(10mM NaCl, 1.5 mM MgCl2, 20 mM HEPES, 20% glycerol, 0.1% Triton x-100, 1mM
dithiothreitol, pH 7.4). The homogenates were centrifuged at 1,000 rpm for 1 minute at 4°C, and
subsequently, the supernatants were collected containing the cytoplasmic extracts. Protease
inhibitor cocktail (Sigma #8340) was added to these samples. After collecting the cytoplasmic
extract, the remaining nuclear pellet was suspended in 100 uL of lysis buffer, and 11 uL of 5M
NaCl was added to lyse the nuclei. This mixture was then rocked for 2h at 4°C and subsequently
centrifuged at 14,000 rpm for 15 minutes at 4°C. The resulting supernatant was collected
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containing the nuclear fraction and protease inhibitor cocktail was added to these samples. These
collected samples were then used for western blot analyses.
Transfection of CRISPR/CAS9 Plasmids
C2C12 myoblasts were transfected with CRISPR/Cas9, GFP (Santa Cruz Biotechnology)
plasmids to create Sirt2 knockdown and control plasmid cell lines. Cells were seeded in 6-well
plates and grown to 40% confluency. At this time the cells were incubated in 3ml of antibiotic free
standard growth media per well 24 hours before the transfection. Plasmid DNA was transfected at
1ug per well with 10ul of transfection reagent media as described in the Santa Cruz protocol for
CRISPR transfection. After 24 hours the antibiotic free media was replaced with normal growth
media containing 1% antibiotic/antimycotic. Transfection efficiency was visually confirmed by
detection of the green fluorescence protein (GFP) via fluorescent microscopy. GFP positive cell
lines were then isolated via FACS cell sorting to create pure cell lines. These isolated cells (GFP
positive) were then sub-cultured to create a population of stably transfected cells which were used
for a variety of assays.
FACS- Cell Sorting
CRISPR-CAS9 transfected cells were isolated and collected from 6-well plates. The cells
were homogenized in sorting buffer (1x PBS, 2.5mM EDTA, 1% FBS, 25mM HEPES, pH 7.0)
and sorted using a FACS Aria cell sorter at the WVU flow cytometry core. Cells were then isolated
into two populations (Sirt2 knockdown, control plasmid) via the GFP tag incorporated into the
plasmids. Sorted cells were then plated and grown for subsequent assays via normal cell culture
protocol.
Immunoprecipitation
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Each collected protein sample was first pre-cleaned and incubated with 25µL of
homogenized protein A/G beads (Invitrogen) for 1 hour with rotation at 4°C. Beads were then
separated from protein using a magnetic separator. The supernatant volume was then increased to
500µL using lysis buffer and 2ug of primary antibody were added to each sample (Rb1, Thermo
Fisher Scientific). The antigen and antibody solution was then incubated for 2 hours at 4°C with
rotation. New magnetic protein A/G beads will be cleaned 3x using wash buffer (Tris Buffered
Saline containing 0.05% Tween-20 detergent and 0.5M NaCl). Antigen and antibody solution
was then added to clean A/G beads and allowed overnight incubation with rotation at 4°C. Beads
were then separated using a magnetic separator and the flow through was saved for analysis. The
magnetic beads were washed 3x in 500µL of IP wash buffer for 30 minutes with rotation. A
single wash of 500µL of distilled H2O followed the wash with IP wash buffer to release the
collected protein from the beads. These beads were then collected by the magnetic apparatus and
the water supernatant was discarded. Next 30µL of 1x sample buffer (8uL 4x NuPAGE LDS
sample buffer, 21uL cell lysis buffer, 2.8uL DTT) were loaded to each tube of beads and heated
at 70°C for 10 minutes. The beads were then separated and discarded while the flow through was
loaded into 4-12% bis-tris gel and a Western Blot protocol was performed on the pull-down.
Real-Time PCRTotal RNA was isolated from the cells using an RNeasy min kit and then treated with
DNase I. First-strand cDNA was synthesized from 1 μg total RNA by reverse transcription in a
20-μl reaction using a SuperScript III RT first-strand cDNA synthesis kit (Invitrogen). Primers
for Sirt1-7 were used with a concentration of 10uM;
Invitrogen primers:
Mus musculus sirtuin 1 (NM_001159589)
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Sirt1 F:
Sirt1 R:

ATGACGCTGTGGCAGATTGTT
CCGCAAGGCGAGCATAGAT

Mus musculus sirtuin 2 (NM_001122766)
Sirt2 F:
CCACGGCACCTTCTACACATC
Sirt2 R:
CACCTGGGAGTTGCTTCTGAG
Mus musculus sirtuin 3 (NM_001127351)
Sirt3 F:
CTGACTTCGCTTTGGCAGAT
Sirt3 R:
GTCCACCAGCCTTTCCACAC
Mus musculus sirtuin 4 (NM_001167691)
Sirt4 F:
GTGGAAGAATAAGAATGAGCGGA
Sirt4 R:
GGCACAAATAACCCCGAGG
Mus musculus sirtuin 5 (NM_178848).
Sirt5 F:
GCAGACGGGTTGTGGTCAT
Sirt5 R:
CTGGGCAGATCGGACTCCTA
Mus musculus sirtuin 6 mRNA (NM_181586)
Sirt6 F:
TCGGGCCTGTAGAGGGGAGC
Sirt6 R:
CGGCGCTTAGTGGCAAGGGG
Mus musculus sirtuin 7 mRNA (NM_153056)
Sirt7 F:
Sirt7 R:

CAATCCTGTGTTTAGGGTCCAG
GTTCACGATGTAGAGTTTGGGTC

Mus musculus GAPDH
F:
GAAGGTGAAGGTCGGAGTCA
R:
TGGAAGATGGTGATGGGATT
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) primers were utilized as internal controls.
Ambion DNase1 (Cat#AM2222) was used to purify the samples of genomic DNA. Real-time
PCR (qPCR) was performed in a Mx3005P qPCR system using Brilliant SYBR green qPCR
Master Mix according to the manufacturer’s procedures (Bioline).The amount of mRNA
transcripts (2−ΔCT) were estimated by the comparative CT (ΔCT) method and normalized to an
endogenous reference (GAPDH) relative to a calibrator.
Statistics
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The data are presented as means ± SEM and multiple t-tests were used to assess statistical
significance with p<0.05. All test were run in triplicate.

Chapter 4 – Results
Specific Aim 1: Establish the role and investigate the mechanisms by which Sirt2 mediates
myoblast differentiation.
The working hypothesis is that Sirt2 levels and
activity are increased during the early differentiation of
myoblasts, and the loss of Sirt2 levels inhibit myoblast
differentiation, thereby Sirt2 positively regulates the
myogenic program.

Figure 3: C2C12 myoblasts were cultured (4x105 cells/well) in growth medium
(GM) containing 10% FBS for two days in six-well plates .Differentiation was
induced by replacing GM by differentiation medium (DM), which contains 2%
horse serum instead of FBS. Total RNA and cell lysate were isolated from cells
in the DM at the indicated time points. Sirtuin mRNA levels were determined
by qPCR. GAPDH gene was used as an internal control and a normalizer.  = p
< 0.05 versus 0 h and δ = p < 0.05 versus 12 and 48 h.

Figure 4: (A) Protein expression of Sirt2 was measured at
each time point by immunoblot. Cyclophilin was used as a
loading control and normalizer. (B) Protein expression of
Ac-α-Tubulin (C) Relative expression levels of Sirt2. *
p<0.05 compared to 0h. Data presented as means ± SEM
with n=3
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Figure 5: Protein expression of muscle transcription factors. (A) Representative immunoblot images of
MRF proteins MyoD and Myogenin. (B-C) Quantification of the relative protein expression levels of
MyoD and Myogenin normalized to cyclophilin. The * represents a significant difference from the 0h
time point with p <0.05. The data are presented as means ±SEM with n=3.
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Figure 6a: Immunoblot of Sirt2 protein levels after transfection
with a Sirt2 knockdown CRISPR/CAS9 plasmid. * represents a
significant difference from CC with the p-value <0.05. The data
are presented as means ±SEM with n=3.
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elevated at the 24h time point as well. This trend remained constant over the course of our
experimentation, with many sample groups supporting this differential Sirt2 protein regulation
during the early stages of myoblast differentiation. The expression of Acetylated-α-Tubulin was
also measured and was decreased at the 12h time point, corresponding to the increased Sirt2 level.
As Acetylated-α-Tubulin is a deacetylation target of Sirt2 this suggest Sirt2 is active at the 12h
time point. The protein expression levels of myogenic transcription factors were also measured
(Fig. 5). MyoD expression increased during the early stages of myogenesis and was significantly
increased at the 12h and 24h time points. This expression coincides with the transient increase in
Sirt2 expression that was previously observed. This MyoD expression was then observed to
decrease as the expression of myogenin was increased. Myogenin is necessary for the

Figure 6b: Sirt2 protein expression in wild type (-) and CRISPR/Cas9 (SKO) (CC) cell lines. (A) Representative immunoblot images of
Sirt2 and cyclophilin protein expression. (B) Quantification of the relative protein expression levels of Sirt2 normalized to cyclophilin.
The * represents a significant difference from wild type (-) cells at the corresponding time point with p<0.05. The data are presented
as means ± SEM with n=3.
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differentiation and fusion of myoblasts, and
the induction of myogenin at these time
points coincides with the formation of
myotubes in the C2C12 cells.
In order to elucidate the mechanism/s
by which Sirt2 regulates the differentiation
of myoblasts, we inhibited Sirt2 both
pharmacologically using the Sirt2 inhibitor
(BML-266), which impairs the deacetylase
activity of Sirt2 without knocking down its
protein expression [67], and also knockdown
of Sirt2 protein expression using a
CRISPR/Cas9 plasmid (Fig. 6a). The
expression of Sirt2 was significantly
decreased following transfection of the
CRISPR/Cas9 knockdown plasmid. Sirt2
knockdown in the SKO cells was not
observed in the cells transfected with the
CRISPR/Cas9 control plasmid, and Sirt1
levels also remained consistent between the
groups. The protein expression of Sirt2 was
also measured over the time course of
myogenesis in the wild type and

Figure 7: (A) Immunocytochemistry for C2C12 cells of each cell group, (-),
SKO, CC at 96h. The panels show representative images at the 96h time
point. The cells are stained with an antibody for non-specific myosin heavy
chain (mf20 green), and overlaid with DAPI nuclear stain. (B) MT+
represents the amount of nuclei incorporated into myotubes. MTrepresents the number of nuclei which were not incorporated into
myotubes. (C) calculation of the myotube fusion index: MT+/Total nuclei.
Data were collected by counting nuclei from 5 representative images (20x)
of myotubes cultures on coverslips. * represents difference from (-) with pvalue <0.05. # <0.01 and presented as means ± SEM
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CRISPR/Cas9 groups (Fig. 6b). The observed protein expression for Sirt2 was significantly
reduced at several time points in the SKO group. However it was significantly increased at later
time points (72h and 96h). The Sirt2 expression levels in the (-) and CC groups were not
significantly different.
The onset of myoblast differentiation could represent a critical point for Sirt2 guided
regulation of myogenesis, and we have demonstrated that inhibition of Sirt2 via BML-266 and
CRISPR/CAS9 knock down, results in a decrease in myotube formation (Fig. 7). The observed
numbers of nuclei incorporated into myotubes (defined as a cell having a minimum of 3 nuclei),
were significantly decreased in the 3uM and 5uM BML-266 groups, and in the SKO Sirt2
knockdown group. The total number of nuclei observed was significantly decreased in all

Myotube Fusion-Inhibition of Sirt2 with BML-266 at 96h

Figure 8: Representative C2C12 myotubes following 96 hours of differentiation in the presence of various concentrations of the Sirt2
deacetylase inhibitor BML-266. These data show that with increasing concentrations of BML-266 the formation of myotubes becomes
progressively worse. At very high concentrations (7.5-10uM) there is large amounts of apoptosis and the cells appear small and
unhealthy. In addition to the decrease in total nuclei observed in the myotube fusion indices this apoptosis and general unhealthy cell
state may indicate non-specific cytotoxicity in the pharmacologically treated groups.

27

pharmacologically treated groups, but not in the CRISPR/Cas9 cell groups. This suggests that
there could be non-specific cytotoxic effects occurring in the pharmacologically treated groups
which must be taken into account when interpreting these results. Calculation of a myotube
fusion index (% nuclei incorporated into myotubes/total nuclei observed) yielded significant
decreases in the 3uM, 5uM, and SKO groups. The observed reduction in the myotube fusion
index of these Sirt2 deficient cells was accompanied by differences in the phenotypes of the
various groups. Myotube morphology was visibly impaired by different concentrations of BML266 (Fig. 8) at the 96h time point. The formation of myotubes was significantly reduced as
higher levels of BML-266 were used. This coincided with a reduction in multinucleated
myotubes and the total numbers of nuclei present within the samples.
In the SKO samples, the morphology of the C2C12 cells was largely normal with healthy
myoblasts being observed at later time points in which myotubes are usually present. The
CRISPR/CAS9 transfected cells are shown (Fig. 9). These pictures show both the control

Figure 9: Representative Images of CRISPR/CAS9 transfected C2C12 cells with both the control plasmid (CC) and the knockout plasmid (SKO at the
72h 96hr time points. CC cells appear to be developing myotubes at a faster rate than cells of the SKO line.
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CRISPR (CC) and Sirt2 knockout (SKO) cells at the 96-hour time point after serum starvation
induced differentiation. SKO cells appear to have a higher percentage of myoblasts than the CC
cells at the 96hr time point after the induction of differentiation. This is supported by the
calculation of the myotube fusion index in figure 7.
Specific Aim 2: Investigate the molecular signaling networks through which Sirt2 promotes
myoblast differentiation.
The working hypothesis is that Sirt2 promotes the differentiation of myoblasts by directly
targeting and deacetylating cell cycle regulators such as pRB or E2F1. As a result of these
interactions, proliferating myoblasts exit the cell cycle and enter into the differentiation program.
To identify the potential downstream protein interactions of Sirt2 immunoprecipitation
experiments were performed. The results of one of these experiments are shown in figure 10.

Figure 10: Immunoprecipitation pulldown assay of pRB. Representative images from pulldown of retinoblastoma (pRB) and subsequent immunoblot.
Pulldown of pRB was accompanied by both Sirt2 and E2F1, both members of the proposed complex associated with the regulation of C2C12
differentiation by Sirt2. Wild type (-) cells showed a peak pRB/Sirt2 association at the 12h time point, consistent with the elevated Sirt2 protein
levels at this time.

Pulldown of the retinoblastoma protein pRB revealed the presence of both Sirt2 and the
proliferation inducing transcription factor E2F1. Sirt2 association with pRB was shown to peak at
12h in the wild type cells, corresponding to the transient increase in Sirt2 protein expression
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previously observed. This association supports the proposed complex between pRB and Sirt2, with
their association leading to the deacetylation of E2F1 thereby silencing the transcriptional
signaling of myoblast proliferation and providing the stimulus for the onset of differentiation.
Pulldown of acetylated lysine was also performed and the acetylation status of E2F1 was
measured to evaluate the function of the protein association observed in Fig. 10. Figure 11 shows
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Figure 11: Acetylation status of E2F1 following pulldown of Ac-Lysine. * represents a significant difference from corresponding (-) time point with
p<0.05. The δ represents a significant difference from 0h of the corresponding cell line. Data are presented as means ± SEM with n=3.

the observed immunoprecipitation results. The acetylation status of E2F1 was significantly
decreased at the 12h time point in the wild type (-) cells. The Sirt2 knockdown cell line exhibited
a significantly increased E2F1 acetylation status indicating that the decreased level of Sirt2 present
in these cells accounted for this increase.
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In addition to the proteins involved in
the proposed complex (pRB, Sirt2, E2F1) p21
was also observed in the pull down of pRB (Fig.
12). Expression of p21 follows the same general
trend seen in various other assays with an
expression of p21 experiencing a transient
increase at the 12h time point. This expression
was coupled with a decrease in p21 expression

Figure 12: Protein levels of p21 in the principle cells lines following
pulldown of pRB. Expression of p21 is decreased at the 12h and 48h time
points in comparison to the (-) cell line. The observed expression of p21 is in
accordance with the proposed pRB differentiation inducing complex as p21
promotes the activity of pRB by inhibiting the phosphorylation of pRB. This
phosphorylated pRB would thus be inactivated and unable to exert influence
on downstream targets such as E2F1.

in the SKO cell line at the 12h and 48h time
points following the general trends of Sirt2 regulation. This regulation of p21 supports the
proposed pRB/Sirt2 differentiation complex, as p21 is a positive regulator of pRB activity.
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Chapter 5 – Discussion and Conclusions
By the observations made throughout this experimentation, we propose that the NAD+
dependent sirtuin protein, Sirt2, transiently migrates to the nucleus during the early stage of C2C12
myoblast differentiation and promotes the differentiation process of these cells to become
myotubes. We have observed a transient increase in the levels of Sirt2 protein during the early
stages of C2C12 myogenesis, followed by the induction of differentiation upon serum starvation.
The increased levels of Sirt2 are present when the C2C12 cells cease proliferation and exit from
the cell cycle. This exit subsequently promotes the differentiation and fusion of myoblasts into
myotubes. It appears that Sirt2 participates in the regulation of this mechanism through an
association with the retinoblastoma protein, which leads to the eventual deacetylation and silencing
of the proliferation inducing transcription factor E2F1.
The sirtuin family of proteins are known deacetylases and are involved in the regulation of
a myriad of processes. Regarding muscular biology, the sirtuin family members, Sirt1 and Sirt3
have previously characterized roles that help regulate myogenesis, and the successful development
and maintenance of healthy muscle fibers. For example, Sirt1 has been implicated as a positive
regulator of myoblast proliferation. Sirt1 is recruited to muscle regulatory regions on chromatin
and interacts with a MyoD/PCAF transcriptional complex and an MEF2 complex further
downstream. Sirt1 can deacetylate and silence these transcription factors, thereby inhibiting
C2C12 myoblast differentiation [67]. This inhibition of differentiation thus allows the myoblasts
to remain in the growth and proliferative stage enabling the formation of a large pool of myoblasts
which can later be used for myotube formation and the replenishment of the activated satellite cell
pool. Sirt1 is also known to promote the proliferation of C2C12 myoblasts through the inhibition
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of cell cycle inhibitors, such as p21 Waf/Cip1 and p27 Kip1 [68]. The mitochondrial sirtuin, Sirt3,
is also involved in the regulation of myogenesis through positive regulation of myogenic
differentiation [11], as Sirt3 deficient C2C12 myoblasts exhibited a marked decrease in the
myoblast fusion index and a significant reduction of myogenic regulatory factor expression.
The close associations between these sirtuins (1, 3), and myogenesis prompted our interest
in the cytosolic Sirt2, as Sirt2 shares classification with 1 and 3 as class 1 sirtuins. Therefore,
exploring the regulation of Sirt2 during myogenesis was of particular interest. Initially, we sought
to investigate the regulation of Sirt2 during the process of differentiating C2C12 myoblasts in
vitro. This led to the observation that Sirt2 protein expression is transiently increased during the
early stages of myoblast differentiation, particularly at the 12h time point. The protein expression
of myogenic regulatory factors MyoD and Myogenin was also performed and exhibited significant
increases of MyoD in the early stages of differentiation, followed by the induction of myogenin.
The induction of myogenin corresponds to differentiation and the formation of myotubes. This
observation prompted the utilization of several different cell lines to further elucidate this
regulation, including a wild type line, a line supplemented with a pharmacological inhibitor of
Sirt2, BML-266, and a Sirt2 knockdown (SKO) cell line generated through the use of a
CRISPR/Cas9 plasmid. The following experimentation yielded several interesting results and
helped to form the Sirt2 regulatory picture.
Immunocytochemistry was performed to examine the phenotype and nuclear count of the
C2C12 cells in each cell line. The results of this myotube fusion index in cell groups with inhibited
Sirt2 function (BML-266 3uM, 5uM), or protein expression (SKO) showed inhibited myotube
formation at the 96h time point after the induction of differentiation. This impaired differentiation
resulted in a noticeable decrease in the number of healthy myotubes present in these groups
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indicating that Sirt2 expression and activity plays a key role in the formation of myotubes and
ultimately healthy myofibers. It is interesting that there was such a pronounced inhibition of
myoblast fusion in the SKO group, as the total knockdown of Sirt2 expression compared to wild
type was only approximately 50%. This could be indicative of the necessity for Sirt2 in this
differentiation process, and that other sirtuins, such as Sirt1 or Sirt3 did not take on a compensatory
function in the absence of normal Sirt2 levels, or that they regulate differential functions during
myogenesis. Indeed, the levels of Sirt1 and Sirt3 protein expression did not appear to fluctuate in
the SKO group during the time course we examined and if they did change it did not rescue the
myotube phenotype during this time point. Extending the time course may elicit these
compensatory reactions and rescue a normal phenotype, especially form Sirt3 with its previously
characterized regulation of differentiation, but we have not investigated that possibility at this time.
In addition to examining the expression and regulation of Sirt2 during our time course,
possible downstream targets and effectors of Sirt2 were examined to elucidate the mechanisms by
which Sirt2 promotes differentiation. Likely targets were identified as members related to the cell
cycle, and exit from the cell cycle in particular. Previous studies have shown that Sirt2 can
transiently migrate to the nucleus during the G2/M phase of the cell cycle and associate with
chromatin structures [25,75]. This observation put Sirt2 in the nucleus during the cell cycle growth
phase and prompted the hypothesis that Sirt2 can associate with transcription factors involved in
cell cycle exit and subsequent differentiation. The retinoblastoma protein pRB was identified as a
possible Sirt2 effector for its role as a regulator of differentiation in various cell types. For
example, pRB is necessary for the completion of the muscle differentiation program and myogenic
helix-loop-helix dependent transcription through a transcriptional link with MyoD [101].
Immunoprecipitation experimentation was performed on wild type, and CRISPR/Cas9 modified
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cell lines to identify protein Sirt2 protein interactions that could contribute to the positive
regulation of differentiation Sirt2 displays. The results of these assays showed the interaction
between Sirt2 and pRB which appeared to peak at the 12h time point corresponding to the protein
upregulation of Sirt2. In addition to pRB, p21 and the transcription factor E2F1 were also present
in the immunoprecipitation assay. The associations displayed here led to the proposed model
shown in Fig. 2. The hypothesis formed by this model involves the partnership of Sirt2 and pRB
through the pRB binding domain. This complex is supported by previous observations of pRB
forming a complex with HDACs and thereby leading to the deacetylation of E2F1 by HDAC
resulting in the cessation of proliferation and the beginning of terminal differentiation. The results
of the IP experimentation support the formation of such a complex during the time course of
myogenesis, and the acetylation status of E2F1 is significantly increased at the 12h time point in
the SKO cell line, indicating that this complex was not able to form in those cells. The presence
of p21 further shows that this complex exists and is related to the cell cycle and that Sirt2 plays a
key role in mediating the switch from proliferation to differentiation.
There are significant implications raised by the results of this experimentation, including
the ability of muscle fibers to regenerate and repair in aging. It is known that levels of the sirtuin
proteins decrease with age, and the activity of the sirtuin cofactor NAD+ is also impaired. This
could impact the ability of satellite cells to proliferate in the case of Sirt1, and impairment in the
ability of aged muscle fibers to regrow and repair in the event of Sirt2 deficiency. This may be a
major contributor to the condition of sarcopenia and strategies aimed at supplementing sirtuin
levels and activity in aged conditions may prove vital to improving the quality of life and
rehabilitation outcomes in old individuals. Future work should be aimed towards validating these
Sirt2 mechanisms in animal models and examining both the structure and function of muscles in
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both knockout and overexpression models. For example, at this time it is necessary to translate the
mechanisms discovered in the C2C12 myoblasts to animal models to examine the efficacy of this
model in vivo. Transgenic mice will be developed to further elucidate these Sirt2 mechanisms.
Sirt2-/- and Sirt2STOP (global over expresser) mice will be acquired from the Jackson Laboratory
and subsequently crossed with several models in our laboratory to develop several different
genotypes using the Cre/loxP system. We will generate tissue specific Sirt2-/- mice for both Pax7+,
(satellite cell knockout) and MCK, (muscle specific knockout). The same strategy will be used to
generate tissue specific overexpression of Sirt2 in both the SC and muscle. Upon generation of
these genotypes various experiments and assays will be performed to assess a variety of factors
including muscle morphology, performance/physiology, protein content, RNA analysis, and
recovery from injury following cardio toxin injection into the muscle. We will also examine this
regulation in both young and aged mice to help elucidate any changes that occur with Sirt2
regulation of the muscles in aging, as both sirtuin and NAD+ levels decrease with age. These
experiments will serve to examine the activity of Sirt2 in vivo and determine whether or not it
regulates myogenesis and myoblast differentiation in a more translational system. This will serve
to increase our understanding of the role Sirt2 plays in the process of myogenesis, and how that
process is altered with aging or disease.
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Appendix
A.) Plasmid design used for Sirt2 KO experiments (Santa Cruz Biotechnology).

